Concord Drugs Profile
Key Indicators
- Authorised Capital ₹ 11.00 Cr
as on 12-12-2024
- Paid Up Capital ₹ 10.00 Cr
as on 12-12-2024
- Company Age 29 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 18.25 Cr
as on 12-12-2024
- Satisfied Charges ₹ 7.40 Cr
as on 12-12-2024
- Revenue 14.78%
(FY 2022)
- Profit -51.42%
(FY 2022)
- Ebitda 73.69%
(FY 2022)
- Net Worth 5.96%
(FY 2022)
- Total Assets 13.16%
(FY 2022)
About Concord Drugs
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 538965.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 11.00 Cr and a paid-up capital of Rs 10.00 Cr.
The company currently has active open charges totaling ₹18.25 Cr. The company has closed loans amounting to ₹7.40 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Concord Drugs Limited India are Koni Seelam as CFO and Namratha as Company Secretary. Nagi Seelam, Ramchandra Kommula, Koni Seelam, and Three other members serve as directors at the Company.
- CIN/LLPIN
L24230TG1995PLC020093
- Company No.
020093
- Stock Symbol
BSE : 538965
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
24 Apr 1995
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Listed
- ROC Code
Roc Hyderabad
Industry
Company Details
- LocationNa, Telangana
- Telephone
- Email Address
- Website
- Social Media
What products or services does Concord Drugs Limited offer?
Concord Drugs Limited offers a wide range of products and services, including Hand Sanitizer & Disinfectant, Alcohol Based Hand Sanitizer.
Who are the key members and board of directors at Concord Drugs?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Koni Seelam  | CFO | 30-Sep-2021 | Current |
| Nagi Seelam | Managing Director | 04-Apr-2003 | Current |
| Namratha | Company Secretary | 08-Apr-2024 | Current |
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Koni Seelam | Whole-Time Director and Cfo | 10-Jun-2011 | Current |
| Ramchandra Kommula | Director | 30-Mar-2019 | Current |
| Seelam Manojkumarreddy | Whole-Time Director | 13-Aug-2021 | Current |
| Nagavenkatahareeshkumar Solleti | Director | 13-Feb-2021 | Current |
| Sumeela Kasu | Director | 01-Jun-2022 | Current |
Financial Performance of Concord Drugs.
Concord Drugs Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 14.78% increase. The company also saw a substantial fall in profitability, with a 51.42% decrease in profit. The company's net worth moved up by a moderate rise of 5.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Concord Drugs?
In 2022, Concord Drugs had a promoter holding of 49.00% and a public holding of 50.99%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Proton Remedies Private LimitedActive 16 years 3 monthsKoni Seelam and Seelam Manojkumarreddy are mutual person
- Cortex Laboratories Private LimitedActive 29 years 6 months
Seelam Manojkumarreddy is a mutual person
- Seelam Laboratories Private LimitedActive 14 years 6 months
Seelam Manojkumarreddy is a mutual person
- Continental Pellets Pharma Private LimitedActive 4 years 10 months
Seelam Manojkumarreddy is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 17 Dec 2011 | ₹18.25 Cr | Open |
Others Creation Date: 11 Mar 2022 | ₹5.00 Cr | Satisfied |
Punjab National Bank Creation Date: 10 Nov 2005 | ₹1.40 Cr | Satisfied |
How Many Employees Work at Concord Drugs?
Concord Drugs has a workforce of 21 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Concord Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Concord Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
